DE971033T1 - Prüfung und Modell für Alzheimers-Krankheit - Google Patents

Prüfung und Modell für Alzheimers-Krankheit

Info

Publication number: DE971033T1
Authority: DE; Germany
Prior art keywords: amino acid; model; exam; disease; alzheimer
Prior art date: 1991-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE0971033T

Other languages

English (en)

Inventor

John Anthony Hardy

Marie-Christin Chartier-Harlin

Alison Mary Goate

Michael John Owen

Michael John Mullan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Imperial College of Science Technology and Medicine

Original Assignee

Imperial College of Science Technology and Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2001-05-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE971033(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Imperial College of Science Technology and Medicine filed Critical Imperial College of Science Technology and Medicine

2001-05-03 Publication of DE971033T1 publication Critical patent/DE971033T1/de

Status Pending legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

DE0971033T 1991-01-21 1992-01-21 Prüfung und Modell für Alzheimers-Krankheit Pending DE971033T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease

Publications (1)

Publication Number	Publication Date
DE971033T1 true DE971033T1 (de)	2001-05-03

Family

ID=26298303

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Country Status (10)

Country	Link
US (3)	US5877015A (de)
EP (2)	EP0568575B2 (de)
JP (3)	JP3510244B2 (de)
AT (2)	ATE447016T1 (de)
AU (1)	AU652997B2 (de)
CA (2)	CA2101774C (de)
DE (3)	DE971033T1 (de)
DK (2)	DK0971033T3 (de)
ES (2)	ES2335720T3 (de)
WO (1)	WO1992013069A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2335720T3 (es)	1991-01-21	2010-03-31	Elan Pharmaceuticals, Inc.	Ensayo y modelo para la enfermedad de alzheimer.
EP0613560B2 (de) *	1991-11-12	2006-06-21	Prana Biotechnology Ltd	Verfahren zur bestimmung und behandlung von alzheimer-krankheit
CA2126451A1 (en) *	1991-12-24	1993-07-08	Brett P. Monia	Compositions and methods for modulating .beta.-amyloid
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
EP0620849B1 (de) *	1992-01-07	2003-06-25	Elan Pharmaceuticals, Inc.	Transgene tiermodelle fur alzheimer-krankheit
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
EP1001019A1 (de) *	1993-10-27	2000-05-17	Athena Neurosciences, Inc.	Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
EP0742831B1 (de)	1994-01-27	2004-09-29	The Regents Of The University Of Minnesota	Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH10504964A (ja) *	1994-09-01	1998-05-19	メルクエンドカンパニーインコーポレーテッド	家族性型ヒトアミロイド前駆タンパク質を発現するトランスジェニック動物
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
EP0832205A1 (de) *	1995-06-07	1998-04-01	Athena Neurosciences, Inc.	Methode zur identifizierung von arzneimitteln gegen der alzheimer krankheit mittels transgener tiermodelle
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
EP1025121B1 (de) *	1997-10-24	2011-08-24	Aventis Pharma S.A.	Peptide die die wechselwirkung zwischen presenilinen und beta-amyloidpeptid oder seinem vorläufer hemmen
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
CN1300320C (zh)	1998-09-24	2007-02-14	法玛西雅厄普约翰美国公司	阿尔茨海默氏疾病分泌酶
US6699671B1 (en) *	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en) *	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
EP1165609A2 (de)	1999-02-10	2002-01-02	Elan Pharmaceuticals, Inc.	Menschliches beta-secretase enzym, inhibitoren und ihre zusammensetzungen und verwendungen
US6355425B1 (en)	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
AU2914501A (en) *	1999-12-28	2001-07-09	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
ES2275675T3 (es) *	2000-03-23	2007-06-16	Elan Pharmaceuticals, Inc.	Compuestos y metodos para tratar la enfermedad de alzheimer.
CA2410972A1 (en)	2000-06-30	2002-01-10	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
EP1297132A1 (de) *	2000-07-06	2003-04-02	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Eine weitere app mutation, die mit einer ungewöhnliche alzheimerkrankheitspathologie verbunden ist
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA03011046A (es) *	2001-06-01	2004-06-25	Elan Pharm Inc	Hidroxialquilaminas.
MXPA03011521A (es)	2001-06-13	2004-03-18	Elan Pharm Inc	Aminadioles para tratamiento de enfermedad de alzheimer.
US6982264B2 (en) *	2001-06-27	2006-01-03	Elan Pharmaceuticals, Inc.	Substituted alcohols useful in treatment of Alzheimer's disease
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
CA2453444A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Diaminediols for the treatment of alzheimer's disease
JP2005505517A (ja) *	2001-07-10	2005-02-24	イーランファーマスーティカルズ、インコーポレイテッド	アルツハイマー病を治療するためのアミンジオール
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
BR0213139A (pt)	2001-10-04	2004-08-10	Elan Pharm Inc	Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
IL161881A0 (en) *	2001-11-08	2005-11-20	Upjohn Co	N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
MXPA04004713A (es) *	2001-11-19	2005-08-16	Pharmacia & Up John Company Ll	Aminoides utiles en el tratamiento de la enfermedad de alzheimer.
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
WO2003072041A2 (en) *	2002-02-27	2003-09-04	Merck & Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
EP1565428A1 (de) *	2002-11-27	2005-08-24	Elan Pharmaceuticals, Inc.	Substituierte harnstoffe und carbamate
ZA200505782B (en)	2003-02-01	2006-09-27	Neuralab Ltd	Active immunization to generate antibodies to soluble A-beta
MXPA05011150A (es) *	2003-04-21	2005-12-14	Elan Pharm Inc	2-hidroxi-3-diaminoalcanos de benzamida.
WO2004094413A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
US20060014790A1 (en) *	2004-01-21	2006-01-19	Varghese John	Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
US20050239832A1 (en) *	2004-03-09	2005-10-27	Varghese John	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
CA2558036A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
CA2558249A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2558034A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
CA2567223A1 (en) *	2004-05-19	2005-11-24	Boehringer Ingelheim International Gmbh	Treatment of diseases associated with altered level of amyloid beta peptides
WO2006010094A1 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals, Inc.	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US7385085B2 (en) *	2004-07-09	2008-06-10	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006026533A2 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006052691A2 (en) *	2004-11-05	2006-05-18	Wyeth	Pet and magnetic resonance for screening alzheimer's disease therapeutics
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
EP2529619B1 (de)	2005-02-17	2015-09-23	Biogen MA Inc.	Behandlung neurologischer Störungen
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
AU2006244014B2 (en)	2005-05-10	2011-03-17	Biogen Ma Inc.	Treating and evaluating inflammatory disorders
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
CA2617294A1 (en) *	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618019A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Compounds for the treatment of alzheimer's disease
CA2618474A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Compounds for treating alzheimer's disease
US20100144681A1 (en) *	2005-08-11	2010-06-10	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
WO2007017507A1 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
EP1937638A1 (de) *	2005-10-12	2008-07-02	Elan Pharmaceuticals Inc.	Verfahren zur behandlung von amyloidose unter verwendung von aspartylproteaseinhibitor- arylcyclopropylderivaten
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007092839A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092854A2 (en)	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2008042024A2 (en)	2006-06-01	2008-04-10	Elan Pharmaceuticals, Inc.	Neuroactive fragments of app
EP2041270B1 (de)	2006-07-13	2013-11-20	Wyeth LLC	Expression von glykoproteinen
EP2089417B1 (de)	2006-10-12	2014-12-31	BHI Limited Partnership	Verfahren, verbindungen, zusammensetzungen und vehikel zur verabreichung von 3-amino-1-propansulfonsäure
WO2008055260A2 (en)	2006-11-03	2008-05-08	Wyeth	Glycolysis-inhibiting substances in cell culture
DK2115126T3 (en)	2007-03-02	2015-05-04	Wyeth Llc	Use of copper and glutamate in cell culture for the preparation of polypeptides
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
EA200971050A1 (ru)	2007-05-11	2010-06-30	Томас Джефферсон Юниверсити	Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EP2164834A2 (de)	2007-07-06	2010-03-24	Boehringer Ingelheim International GmbH	Substituierte aminochinazolinone, medikamente mit einer derartigen verbindung, ihre verwendung und herstellungsverfahren dafür
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
ES2400173T3 (es) *	2008-01-28	2013-04-08	Janssen Pharmaceutica Nv	Derivados de 6-sustituido-tio-2-amino-quinolina útiles como inhibidores de beta-secretasa (BACE)
AU2009209147B2 (en) *	2008-01-29	2013-03-14	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
JP2011514158A (ja) *	2008-02-19	2011-05-06	エダン・バイオテクノロジー・インコーポレイテッド	アミロイドベータタンパク質発現のアンチセンス調節
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
DK2605655T3 (en)	2010-08-19	2019-02-04	Buck Institute For Age Res	METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
CN104270945B (zh)	2012-03-19	2017-03-29	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
DK2864360T3 (en)	2012-06-25	2017-12-18	Brigham & Womens Hospital Inc	TARGETED THERAPY
KR102220259B1 (ko)	2013-02-12	2021-02-25	버크 인스티튜트 포 리서치 온 에이징	Bace 매개 app 처리과정을 조절하는 히단토인
EP3708184A1 (de)	2013-03-27	2020-09-16	The General Hospital Corporation	Verfahren und mittel zur behandlung von morbus alzheimer
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
US11168369B2 (en)	2014-11-25	2021-11-09	The Brigham And Women's Hospital, Inc.	Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US10683552B2 (en)	2014-11-25	2020-06-16	Presidents And Fellows Of Harvard College	Clonal haematopoiesis
AU2016311502B2 (en)	2015-08-27	2019-07-18	Nantneuro, Llc	Compositions for app-selective bace inhibition and uses therfor
EP3455223B1 (de)	2016-05-12	2023-11-08	Buck Institute for Research on Aging	Verbindungen zur förderung der normalen verarbeitung von app

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
DE3689123T2 (de) *	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3702789A1 (de) *	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
WO1989006689A1 (en) *	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
JPH04505261A (ja)	1989-05-10	1992-09-17	スローン―ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ	ポルｉｉｉプロモーターの制御下の転写可能な外来ｄｎａを含む安定的に形質転換された真核細胞
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (de) *	1990-04-10	1991-10-16	Miles Inc.	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
WO1991016628A1 (en) *	1990-04-24	1991-10-31	The Regents Of The University Of California	Purification, detection and methods of use of protease nexin-2
AU646877B2 (en) *	1990-06-15	1994-03-10	Scios Nova Inc.	Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
WO1992000521A1 (en) *	1990-06-29	1992-01-09	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
ES2335720T3 (es)	1991-01-21	2010-03-31	Elan Pharmaceuticals, Inc.	Ensayo y modelo para la enfermedad de alzheimer.
AU2765992A (en) *	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
EP0620849B1 (de) *	1992-01-07	2003-06-25	Elan Pharmaceuticals, Inc.	Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
- 1992-01-21 EP EP92903304A patent/EP0568575B2/de not_active Expired - Lifetime
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
- 1992-01-21 EP EP99109196A patent/EP0971033B1/de not_active Revoked
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en active IP Right Grant
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
CA2372251A1 (en)	1992-08-06
JP3510244B2 (ja)	2004-03-22
ATE286971T1 (de)	2005-01-15
DE69233468D1 (de)	2005-02-17
ES2236682T5 (es)	2011-03-31
JP2004261187A (ja)	2004-09-24
DE69233468T3 (de)	2011-05-05
DK0568575T4 (da)	2010-12-20
JP3574432B2 (ja)	2004-10-06
CA2101774A1 (en)	1992-07-22
JPH06504441A (ja)	1994-05-26
US5877015A (en)	1999-03-02
DK0568575T3 (da)	2005-05-23
EP0971033A2 (de)	2000-01-12
EP0971033A3 (de)	2003-11-12
ES2335720T3 (es)	2010-03-31
EP0568575B1 (de)	2005-01-12
CA2101774C (en)	2011-01-04
ATE447016T1 (de)	2009-11-15
US6300540B1 (en)	2001-10-09
DE69233774D1 (de)	2009-12-10
EP0568575B2 (de)	2010-11-03
JP2002306195A (ja)	2002-10-22
EP0568575A1 (de)	1993-11-10
ES2236682T3 (es)	2005-07-16
DK0971033T3 (da)	2009-12-14
DE69233468T2 (de)	2005-12-22
AU1169492A (en)	1992-08-27
US20030165958A1 (en)	2003-09-04
WO1992013069A1 (en)	1992-08-06
EP0971033B1 (de)	2009-10-28
AU652997B2 (en)	1994-09-15

Publication	Publication Date	Title
DE69233774D1 (de)	2009-12-10	Prüfung und Modell für Alzheimers-Krankheit
DE69839808D1 (de)	2008-09-11	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
DK0868519T3 (da)	2006-05-08	Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
ES2170104T3 (es)	2002-08-01	Inhibidores de la produccion de proteinas de beta-amiloide.
ATE239797T1 (de)	2003-05-15	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DK0528932T3 (da)	1996-07-01	Protein associeret med akut pancreatitis og midler til diagnose af akut pancreatitis
NO931889L (no)	1993-11-29	Protease og beslektede DNA-forbindelser
ATE160361T1 (de)	1997-12-15	Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
DE69333872T2 (de)	2006-06-14	Sonde zur Diagnose einer ansteckenden Krankheit verursacht durch Escherichia coli, Klebsiella pneumoniae oder Enterobacter cloacae
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60133661D1 (de)	2008-05-29	Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
DE68925275D1 (de)	1996-02-08	Endotoxin-bindeprotein und dessen verwendung
EP0716591A4 (de)	1998-02-04	Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
DE50108670D1 (de)	2006-04-06	Verwendung von neuregulin-beta als indikator und/oder target
ATE312914T1 (de)	2005-12-15	Rdgb-proteine
DK0592600T3 (da)	2000-04-17	Protein S polypeptider og anvendelse deraf
DE69519654T2 (de)	2001-05-17	htFIIIA Gen
DE59009360D1 (de)	1995-08-10	Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.